Mitobridge, Inc.
Industry
- Pharmaceuticals
- Biotechnology
- Drug Discovery Technologies
Other Names/Subsidiaries
- Mitokyne, Inc.
Latest on Mitobridge, Inc.
Astellas Pharma, Inc. has effectively ended its interest in the mitochondrial area after a decision to terminate its only candidate, ASP0367 (bocidelpar/MA-0211) in Phase II/III trials, and remove th
October ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OrsoBio Splurges With Four Concurrent L
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Visus Licenses Drugs From Cella, Delive